Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- The first affiliated hospital of Guangzhou MC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological or cytological diagnosis of lung adenocarcinoma histology with brain metastases
- 18 years or older
- Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 3 (poor PS caused by neurological symptom)
- Appraisable intracranial disease, the presence of at least one lesion, and the longest diameter > 5 mm by brain MRI
- Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x 10^9/L
- Total bilirubin 1.5 x upper limit of normal (ULN)
- alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases
- Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)
- If received brain radiotherapy, patients included at least 8 weeks after the end of radiotherapy.
Exclusion Criteria:
- Mixed non-adenocarcinoma cell lung cancer histology
- Previous treatment with pemetrexed or tarceva
- Be allergic to pemetrexed or tarceva
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Erlotinib, pemetrexed, cisplatin
|
150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
Other Names:
500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
Other Names:
cisplatin 20mg/m² iv on the 1st-3rd day (if PS<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
Other Names:
150 mg given orally (po), daily (QD), starting on the first day of the first cycle
Other Names:
|
|
Experimental: erlotinib
|
150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
Other Names:
150 mg given orally (po), daily (QD), starting on the first day of the first cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The objective response rate of brain metastases
Time Frame: Patients will be followed for an expected average of 6 weeks
|
Patients will be followed for an expected average of 6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The disease control response rate of disease
Time Frame: Patients will be followed for an expected average of 6 weeks
|
Patients will be followed for an expected average of 6 weeks
|
|
Progression-free survival of patients
Time Frame: 2 years after first treatment
|
2 years after first treatment
|
|
Number of participants with adverse events as a measure of safety
Time Frame: 2 years after first treatment
|
2 years after first treatment
|
|
Overall survival of patients
Time Frame: 3 years after the first treatment
|
3 years after the first treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Haihong Yang, Dr., The first affiliated hospital of Guangzhou MC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Adenocarcinoma
- Brain Neoplasms
- Adenocarcinoma of Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Folic Acid Antagonists
- Erlotinib Hydrochloride
- Cisplatin
- Pemetrexed
Other Study ID Numbers
Other Study ID Numbers
- GZTO1201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.